Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide effervescent tablet rinse for resistant oral chronic graft versus host disease
2008-004562-10Phase 3Terminated
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Oral chronic graft versus host disease comparing Budesonide rinse with Placebo rinse (2 arms). Primary endpoint: Primary objective response rate. Started Nov 2008; status: terminated.
02
Drugs
budesonide
03
Conditions
Oral chronic graft versus host disease
Beyond the preview
Go deeper on 2008-004562-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004562-10.